Liposomal Cytarabine-Daunorubicin Cpx-351
Adult Acute Megakaryoblastic Leukemia (M7)
Rondeep BrarunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Adult Acute Megakaryoblastic Leukemia (M7) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Northwestern University | Phase 3 | BBB |
Cytosin-Arabinosid University of Alberta | Phase 3 | BBB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BBB |
Daunorubicin ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
Idarubicine University of Alberta | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Liposomal Cytarabine-Daunorubicin Cpx-351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →